Milestone Pharmaceuticals (MIST) Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MIST Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Milestone Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.32 |
| 52 Week High | US$2.75 |
| 52 Week Low | US$0.63 |
| Beta | 0.44 |
| 1 Month Change | 19.59% |
| 3 Month Change | 38.92% |
| 1 Year Change | 36.47% |
| 3 Year Change | -51.05% |
| 5 Year Change | -64.36% |
| Change since IPO | -84.91% |
Recent News & Updates
Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?
Nov 15
Milestone Pharmaceuticals: Playing The Long Ball In Cardiovascular Treatment
Oct 07Recent updates
Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?
Nov 15Milestone Pharmaceuticals: Playing The Long Ball In Cardiovascular Treatment
Oct 07Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?
Nov 06Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely
Jun 07Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?
Sep 13We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
Mar 07We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
Oct 15We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth
Jun 24We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely
Feb 25We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow
Aug 25Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth
Apr 02What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition
Jan 15Shareholder Returns
| MIST | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 25.4% | 4.9% | -2.7% |
| 1Y | 36.5% | 20.3% | 11.9% |
Return vs Industry: MIST exceeded the US Pharmaceuticals industry which returned 19.1% over the past year.
Return vs Market: MIST exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| MIST volatility | |
|---|---|
| MIST Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: MIST has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MIST's weekly volatility has decreased from 15% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 33 | Joe Oliveto | www.milestonepharma.com |
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil.
Milestone Pharmaceuticals Inc. Fundamentals Summary
| MIST fundamental statistics | |
|---|---|
| Market cap | US$203.16m |
| Earnings (TTM) | -US$58.01m |
| Revenue (TTM) | n/a |
Is MIST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MIST income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$58.01m |
| Earnings | -US$58.01m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.57 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 274.2% |
How did MIST perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/17 05:58 |
| End of Day Share Price | 2025/11/17 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Milestone Pharmaceuticals Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrick Trucchio | H.C. Wainwright & Co. |
| Brandon Folkes | H.C. Wainwright & Co. |
| Christopher Howerton | Jefferies LLC |